News & Updates

Show Multimedia Only
Shorter time from rectal cancer diagnosis to NCRT tied to pathologic complete response

Shorter time from rectal cancer diagnosis to NCRT tied to pathologic complete response

08 Jan 2022

The time elapsed between diagnosis of rectal cancer and initiation of neoadjuvant chemoradiation (NCRT) shows a significant association with pathologic complete response (pCR), and shortening this time may improve the likelihood of achieving pCR, suggests a recent study.

08 Jan 2022
Belzutifan a ray of hope for VHL-associated renal cancer?

Belzutifan a ray of hope for VHL-associated renal cancer?

07 Jan 2022 byAudrey Abella

In a phase II study, the novel oral HIF*-2α inhibitor belzutifan showed promise for individuals with renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease, a rare autosomal dominant hereditary disease associated with benign and malignant neoplasms, including clear-cell RCC, pancreatic neuroendocrine tumours, and CNS** and retinal hemangioblastomas.

07 Jan 2022
Ixazomib regimens disappoint in older patients with multiple myeloma

Ixazomib regimens disappoint in older patients with multiple myeloma

06 Jan 2022

Induction with ixazomib-based regimens appear to be insufficient for older patients newly diagnosed multiple myeloma who are ineligible for transplantation, achieving an unsatisfactory progression-free survival (PFS) rate, reports a recent study.

06 Jan 2022